Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CTAD 2022 | Understanding the effect of other diseases on blood biomarker levels in AD

Milica Kramberger, MD, PhD, University Medical Centre Ljubljana, Ljubljana, Slovenia, expresses the need to better understand how concomitant conditions/diseases such as chronic kidney disease (CKD) could interact with blood-based biomarker levels, such as plasma phosphorylated-tau181 (p-tau181), in the screening and diagnosis of early Alzheimer’s disease (AD). In previous clinical studies, CKD patients have been found to be prone to suffering cognitive decline and AD, however the mechanism behind this relation is unclear. For this reason, Dr Kramberger suggests more research into the connections between AD and other diseases, and specifically how this affects how biomarker levels should be interpreted. This interview took place at the Clinical Trials on Alzheimer’s Disease Congress 2022 in San Francisco.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.